- Home
- YHGJ vs EDSA Comparison
YHGJ vs EDSA Comparison
Compare YHGJ & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- EDSA
- Stock Information
- Founded
- YHGJ 1975
- EDSA 2015
- Country
- YHGJ United States
- EDSA Canada
- Employees
- YHGJ N/A
- EDSA N/A
- Industry
- YHGJ Specialty Chemicals
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- EDSA Health Care
- Exchange
- YHGJ Nasdaq
- EDSA Nasdaq
- Market Cap
- YHGJ 17.1M
- EDSA 17.2M
- IPO Year
- YHGJ 1997
- EDSA N/A
- Fundamental
- Price
- YHGJ $0.54
- EDSA $2.30
- Analyst Decision
- YHGJ
- EDSA Strong Buy
- Analyst Count
- YHGJ 0
- EDSA 2
- Target Price
- YHGJ N/A
- EDSA $13.00
- AVG Volume (30 Days)
- YHGJ 191.1K
- EDSA 12.0K
- Earning Date
- YHGJ 11-07-2025
- EDSA 08-08-2025
- Dividend Yield
- YHGJ N/A
- EDSA N/A
- EPS Growth
- YHGJ N/A
- EDSA N/A
- EPS
- YHGJ N/A
- EDSA N/A
- Revenue
- YHGJ $18,964,000.00
- EDSA N/A
- Revenue This Year
- YHGJ N/A
- EDSA N/A
- Revenue Next Year
- YHGJ N/A
- EDSA N/A
- P/E Ratio
- YHGJ N/A
- EDSA N/A
- Revenue Growth
- YHGJ 5.70
- EDSA N/A
- 52 Week Low
- YHGJ $0.43
- EDSA $1.55
- 52 Week High
- YHGJ $1.27
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- YHGJ 39.28
- EDSA 43.90
- Support Level
- YHGJ $0.56
- EDSA $2.41
- Resistance Level
- YHGJ $0.68
- EDSA $2.47
- Average True Range (ATR)
- YHGJ 0.06
- EDSA 0.07
- MACD
- YHGJ 0.00
- EDSA -0.02
- Stochastic Oscillator
- YHGJ 10.00
- EDSA 0.00
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.